Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03405909 | Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study(ESCULAP) | completed | — | 517 | University Hospital ErlangenOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT03338062 | A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy | completed | N/A | 15 | Indiana UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03778593 | FOLFIRINOX for 2nd-line Treatment of BTC | completed | Phase 2 | 34 | Dong-A University HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Karus Therapeutics LimitedINDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT03830606 | The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | completed | Phase 2 | 54 | Aiping ZhouUNKNOWN | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04731220 | A Questionnaire Survey for Biliary Tract Cancers | unknown | — | 12,000 | Kyungpook National University Chilgok HospitalOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03307538 | Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma(STRONG) | completed | N/A | 6 | Erasmus Medical CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | terminated | Phase 1 / Phase 2 | 204 | ASLAN PharmaceuticalsOTHER | 3 | Jan 14, 2021 | clinicaltrials |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer(BILHER) | completed | Phase 2 | 4 | Changhoon YooOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT02579616 | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | completed | Phase 2 | 29 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02597465 | A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 | withdrawn | Phase 3 | 0 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03475966 | Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program | unknown | N/A | 60 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 34 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03438435 | Fluorescence QRH-882260 Peptide Imaging in the Bile Duct | completed | Phase 1 | 1 | D. Kim Turgeon, MDOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03231176 | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | completed | Phase 2 | 62 | ASLAN PharmaceuticalsOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04633382 | ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY | unknown | N/A | 50 | Vitebsk State Medical UniversityOTHER | 0 | Nov 19, 2020 | clinicaltrials |
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | completed | Phase 1 / Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01844245 | Endobiliary RFA for Unresectable Malignant Biliary Strictures | completed | N/A | 174 | Bing HuOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03383796 | Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma | unknown | N/A | 30 | Tongji HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01247337 | Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma | completed | Phase 2 | 56 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04568512 | DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture(DNA) | completed | N/A | 67 | Mahidol UniversityOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01938729 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02428855 | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03411200 | Patient Activation Through Counseling, Exercise and Mobilization(PACE-Mobil) | completed | N/A | 99 | Herlev and Gentofte HospitalOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT04385147 | Advanced Endoscopy During COVID-19 | completed | — | 670 | Al-Azhar UniversityOTHER | 5 | Jul 8, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04386772 | Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma | unknown | N/A | 56 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT00339560 | A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China | completed | — | 2,624 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03579758 | Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer | withdrawn | Phase 3 | 0 | Emory UniversityOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04415190 | the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 2, 2021source: clinicaltrials